ALNYLAM PHARMACEUTICALS, INC.

ALNY 10-K · FY 2025
API behind this page

ALNY FY 2025 request

Playground key active
Request URL /api/financials?ticker=ALNY&year=2025&quarter=4&full_year_mode=true
waiting 0 ms 
Pick an endpoint and run the request.
curl

Income Statement

JSON CSV Excel
Income Statement
Metric FY 2025 FY 2024 YoY
Revenue 3,713,937 2,248,243 +65.2%
Show Product Lines breakouts
AMVUTTRA 2,313,836 970,450 +138.4%
AMVUTTRA · Europe 405,899 235,441 +72.4%
AMVUTTRA · Rest of World 176,715 104,396 +69.3%
AMVUTTRA · US 1,731,222 630,613 +174.5%
C5 License Obligation · Regeneron Pharmaceuticals 21,635 38,341 -43.6%
GIVLAARI 308,487 255,871 +20.6%
GIVLAARI · Europe 77,715 65,906 +17.9%
GIVLAARI · Rest of World 25,057 24,592 +1.9%
GIVLAARI · US 205,715 165,373 +24.4%
License · Roche 300 — —
Net revenues from collaborations 553,366 510,221 +8.5%
Net revenues from collaborations · Vir Biotechnology, Inc. 30 — —
ONPATTRO 172,789 252,857 -31.7%
ONPATTRO · Europe 79,429 134,197 -40.8%
ONPATTRO · Rest of World 31,234 43,873 -28.8%
ONPATTRO · US 62,126 74,787 -16.9%
Other license programs · Regeneron Pharmaceuticals 50,372 33,140 +52.0%
OXLUMO 191,437 167,050 +14.6%
OXLUMO · Europe 88,049 80,753 +9.0%
OXLUMO · Rest of World 34,921 23,531 +48.4%
OXLUMO · US 68,467 62,766 +9.1%
Product 2,986,549 1,646,228 +81.4%
Product And Service Other · Roche 5,879 8,733 -32.7%
Rare 499,924 422,921 +18.2%
Regeneron Technology Transfer Obligation · Regeneron Pharmaceuticals 2,431 — —
Research Services Obligation · Regeneron Pharmaceuticals 39,519 39,097 +1.1%
Roche Development Services Obligation · Roche 89,002 45,756 +94.5%
Roche License Obligation · Roche 300,000 65,000 +361.5%
Royalty 174,022 91,794 +89.6%
TTR 2,486,625 1,223,307 +103.3%
Show Counterparty Name breakouts
Other · Collaborative Arrangement 44,528 8,175 +444.7%
Regeneron Pharmaceuticals · Collaborative Arrangement 113,957 302,798 -62.4%
Regeneron Pharmaceuticals · Global Strategic Collaboration 113,957 302,798 -62.4%
Roche · Collaborative Arrangement 394,881 119,489 +230.5%
Roche · Roche Collaboration and License Agreement 394,881 119,489 +230.5%
Show Type Of Arrangement breakouts
Collaborative Arrangement 553,366 510,221 +8.5%
Cost of Revenue 677,166 306,513 +120.9%
Cost Of Collaboration Manufacturing And Royalties 4,705 16,857 -72.1%
Research & Development 1,319,775 1,126,232 +17.2%
Show Research And Development Expense [Axis] breakouts
Clinical research and outside services 640,672 509,129 +25.8%
Compensation and related 516,208 455,678 +13.3%
Occupancy and all other costs 162,895 161,425 +0.9%
Show Counterparty Name breakouts
Regeneron Pharmaceuticals · Global Strategic Collaboration 62 71.7 -13.5%
Roche · Roche Collaboration and License Agreement 160 92.7 +72.6%
Selling, General & Administrative 1,210,713 975,526 +24.1%
Show Selling, General and Administrative Expense [Axis] breakouts
Compensation and related 668,302 531,078 +25.8%
Consulting and professional services 348,976 274,539 +27.1%
Occupancy and all other costs 193,435 169,909 +13.8%
Total Costs & Expenses 3,212,359 2,425,128 +32.5%
Operating Income 501,578 -176,885 +383.6%
Interest Expense -252,627 -141,858 -78.1%
Interest Income 111,470 121,992 -8.6%
Induced Conversion Of Convertible Debt Expense -42,473 — —
Show Debt Instrument breakouts
Convertible Senior Notes Due 2027 · Convertible Debt -3.3 — —
Other Non-Operating Income (Expense) 5,204 -180,624 +102.9%
Non-Operating Income (Expense) -178,426 -200,490 +11.0%
Income Before Taxes 323,152 -377,375 +185.6%
Income Tax Expense (Benefit) -9,405 99,218 -109.5%
Net Income 313,747 -278,157 +212.8%
Show Equity Components breakouts
Retained Earnings 313,747 -278,157 +212.8%
EPS (Basic) 2.39 -2.18 +209.6%
EPS (Diluted) 2.33 -2.18 +206.9%
Wtd Avg Shares (Basic) 131,004 127,651 +2.6%
Wtd Avg Shares (Diluted) 134,684 127,651 +5.5%
Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax 1,816 -4 +45500.0%
Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent 11,624 -9,643 +220.5%
Other Comprehensive Income Defined Benefit Plans Adjustment Net Of Tax Portion Attributable To Parent 981 -1,496 +165.6%
Other Comprehensive Income 14,421 -11,143 +229.4%
Show Equity Components breakouts
Accumulated Defined Benefit Plans Adjustment 981 -1,496 +165.6%
Accumulated Net Unrealized Investment Gain Loss 1,816 -4 +45500.0%
Accumulated Other Comprehensive Income 14,421 -11,143 +229.4%
Accumulated Translation Adjustment 11,624 -9,643 +220.5%
Comprehensive Income 328,168 -289,300 +213.4%

Balance Sheet

Balance Sheet
Metric FY 2025 FY 2024 YoY
Current Assets
Cash & Cash Equivalents 1,657,250 966,428 +71.5%
Available For Sale Securities Debt Securities Current 1,251,234 1,719,920 -27.3%
Accounts Receivable 777,567 405,308 +91.8%
Show Product Lines breakouts
Product 669.5 269.9 +148.1%
Show Type Of Arrangement breakouts
Collaborative Arrangement 48,823 102,743 -52.5%
Inventory 82,719 78,509 +5.4%
Prepaid Expenses & Other Current Assets 281,892 116,964 +141.0%
Total Current Assets 4,050,662 3,295,285 +22.9%
Non-Current Assets
Property, Plant & Equipment 513,147 502,784 +2.1%
Operating Lease Right-of-Use Assets 194,916 191,148 +2.0%
Deferred Tax Assets 125,975 116,863 +7.8%
Restricted Investments Noncurrent 22,170 68,593 -67.7%
Other Non-Current Assets 59,461 65,310 -9.0%
Total Assets 4,966,331 4,239,983 +17.1%
Current Liabilities
Accounts Payable 115,721 88,415 +30.9%
Accrued Liabilities 1,080,197 793,692 +36.1%
Operating Lease Liability Current 45,518 41,886 +8.7%
Deferred Revenue (Current) 4,845 55,481 -91.3%
Show Product Lines breakouts
Research Services Obligation · Regeneron Pharmaceuticals 4,845 41,156 -88.2%
Show Counterparty Name breakouts
Regeneron Pharmaceuticals 4,845 55,481 -91.3%
Show Type Of Arrangement breakouts
Collaborative Arrangement 4,845 55,481 -91.3%
Royalty And Development Funding Liability Current 220,068 113,018 +94.7%
Show Product Lines breakouts
Vutrisiran 94.5 — —
Zilebesrian 6.8 — —
Show Counterparty Name breakouts
Blackstone Group Inc. 118.8 112.1 +6.0%
Total Current Liabilities 1,466,349 1,186,272 +23.6%
Non-Current Liabilities
Operating Lease Liabilities 225,087 229,541 -1.9%
Convertible Debt Noncurrent 1,007,784 1,024,621 -1.6%
Royalty And Development Funding Liability Noncurrent 1,470,341 1,334,353 +10.2%
Show Product Lines breakouts
Vutrisiran 99.7 — —
Zilebesrian 10.3 — —
Show Counterparty Name breakouts
Blackstone Group Inc. 1.36 1.34 +1.5%
Other Non-Current Liabilities 7,594 4,969 +52.8%
Total Liabilities 4,177,155 4,172,895 +0.1%
Long-Term Debt (Q) — — —
Show Debt Instrument breakouts
2028 Notes · Convertible Debt 647.2 — —
Convertible Senior Notes Due 2027 · Convertible Debt 360.5 1.02 +35243.1%
Stockholders' Equity
Common Stock 1,324 1,293 +2.4%
Additional Paid In Capital Common Stock 7,510,473 7,388,061 +1.7%
Accumulated Other Comprehensive Income -20,097 -34,518 +41.8%
Retained Earnings -6,702,524 -7,287,748 +8.0%
Total Stockholders' Equity 789,176 67,088 +1076.3%
Show Equity Components breakouts
Accumulated Defined Benefit Plans Adjustment -3,268 -4,249 +23.1%
Accumulated Net Unrealized Investment Gain Loss 3,360 1,544 +117.6%
Accumulated Other Comprehensive Income -20,097 -34,518 +41.8%
Accumulated Translation Adjustment 12,603 979 +1187.3%
Additional Paid In Capital 7,510,473 7,388,061 +1.7%
Common Stock 1,324 1,293 +2.4%
Loss on Investment in Joint Venture -32,792 -32,792 0.0%
Retained Earnings -6,702,524 -7,287,748 +8.0%
Total Liabilities & Equity 4,966,331 4,239,983 +17.1%

Cash Flow Statement

Cash Flow Statement
Metric FY 2025 FY 2024 YoY
Operating Activities
Depreciation Amortization And Accretion Net 55,658 56,670 -1.8%
Non Cash Interest Expense On Liabilities Related To The Sale Of Future Royalties And Development Funding 238,399 127,133 +87.5%
Stock-Based Compensation 348,235 272,084 +28.0%
Equity Securities Fv Ni Gain Loss 2,306 3,022 -23.7%
Gains Losses On Extinguishment Of Debt 42,473 — —
Deferred Income Taxes -2,198 -106,762 +97.9%
Other Operating Activities Cash Flow Statement -29,758 -38,988 +23.7%
Change in Accounts Receivable -359,963 -86,550 -315.9%
Change in Inventory 8,474 13,590 -37.6%
Change in Prepaid & Other Assets -117,724 3,229 -3745.8%
Increase Decrease In Accounts Payable And Accrued Liabilities 75,066 91,093 -17.6%
Change in Deferred Revenue -50,635 -235,446 +78.5%
Net Cash from Operations 524,080 -8,312 +6405.1%
Investing Activities
Capital Expenditures -58,697 -34,277 -71.2%
Purchases of Investments -1,305,081 -1,634,911 +20.2%
Proceeds From Sale And Maturity Of Marketable Securities 1,802,257 1,571,665 +14.7%
Proceeds From Sale Of Restricted Investments 59,775 57,875 +3.3%
Payments To Acquire Restricted Investments -59,775 -77,075 +22.4%
Other Investing Activities -2,150 -117 -1737.6%
Net Cash from Investing 436,329 -116,840 +473.4%
Financing Activities
Proceeds From Convertible Debt 645,692 — —
Payment For Option Indexed To Equity -35,311 — —
Repayments Of Convertible Debt -1,154,913 — —
Debt Issuance Costs -2,414 — —
Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options 250,028 302,951 -17.5%
Proceeds From Liabilities Related To The Sale Of Future Royalties And Development Funding 6,000 — —
Repayment Of Liabilities Related To The Sale Of Future Royalties And Development Funding -14,272 — —
Net Cash from Financing -305,190 294,159 -203.8%
Supplemental
Interest Paid 218,707 67,578 +223.6%
Right Of Use Asset Obtained In Exchange For Operating Lease Liability 21,195 9,309 +127.7%
Unpaid Capital Expenditures 10,902 2,324 +369.1%
Income Taxes Paid 15,088 — —
Other Cash Flow
Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents 34,936 -15,239 +329.3%
Net Change in Cash 690,155 153,768 +348.8%
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents 1,658,807 968,652 +71.2%

Values in thousands USD. Source: SEC EDGAR 10-K filing.

This table is rendered from the same JSON returned by /api/financials.

Get API Key